Is There a Problem With Ezetimibe or Just ENHANCEd Hype?
Thomas F. Whayne Jr, MD, PhD previously reported data that ezetimibe accentuates this effect of statins 2 and that a high statin dose is not necessary for this reduction. There is promising data that the reduction of hsCRP has cardiovascular benefit, 3 but this is not yet universally accepted.
These results of ENHANCE unleashed major controversy and, for many physicians and patients, a loss of confidence in their approach to lipid management. For example, there was a quote in The New York Times that the results are "shocking" and that "patients should not be prescribed Zetia (ezetimibe) unless all other cholesterol drugs have failed." 4 Is all this warranted?
Since initial release of the ENHANCE results, the media has weighed in with its analyses. The Wall Street Journal described the negative outcome of the study and what it showed, commenting that since the data were revealed in a news release by drug companies rather than in the usual form of an abstract or a peer-reviewed publication, the details about the safety and effectiveness of the drug can be considered unclear. 5 This Wall Street Journal article quoted Dr. Kevin Graham, president and head of preventive cardiology at the Minneapolis Heart Institute, as saying that it is "premature to use this study (ENHANCE) to change how an entire nation is prescribing medication."
In response to the question of why the drug is on the market if it does not prevent heart attacks, the Wall Street Journal article 5 commented that the Food and Drug Administration (FDA) approved ezetimibe on the basis of its ability to lower LDL-C rather than to reduce the incidence of myocardial infarction, similar to the standard used for many medications for hypertension or diabetes mellitus. This has highlighted the controversy on drug approvals and FDA standards. Also, some physicians, including Dr. Paul Ridker, a preventive cardiologist at Brigham and Women's Hospital in Boston, believe that physicians should prescribe higher doses of statins long before adding a second drug J anuary 2008 saw the release of nonsupportive information on what has been considered an important additional medication in the management of atherosclerosis, coronary heart disease (CHD), and hypercholesterolemia. The ENHANCE (Effect of Ezetimibe Plus Simvastatin Versus Simvastatin Alone on Atherosclerosis in the Carotid Artery) trial, sponsored by Merck/Schering-Plough, opened a hornets' nest of controversy. The purpose of the study was to compare the change in the carotid intima-media thickness (IMT) between patients with heterozygous familial hyper-cholesterolemia treated with ezetimibe/simvastatin 10/80 mg per day versus patients receiving only high-dose simvastatin 80 mg administered for 2 years. 1 A total of 720 patients were randomized in a double-blind fashion: 357 to ezetimibe/simvastatin (group 1) and 363 to simvastatin alone (group 2). The patients were then followed for 24 months. While there was a greater decrease in low-density lipoprotein cholesterol (LDL-C) (58% in group 1 vs 41% in group 2; P < .01) as expected, there was no significant difference between the 2 groups with respect to progression of carotid IMT, the primary endpoint. The IMT progression in group 1 with ezetimibe/simvastatin (0.0111 mm) compared with group 2 with simvastatin alone (0.0058 mm) did not differ significantly (P = .29). Additionally, there were no significant differences in cardiovascular outcomes between the 2 groups. 1 Also, it is intriguing that group 1 with ezetimibe/simvastatin resulted in a 25.7% reduction in high-sensitivity C-reactive protein (hsCRP) as compared to group 2. This is consistent with that has no evidence of improving a patient's chances to avoid a heart attack or stroke. 5 The American College of Cardiology noted that the ENHANCE trial is basically an imaging study and not a clinical-outcomes study. The College recommends that conclusions not be made until clinicaloutcome trials with ezetimibe are completed, and that ezetimibe continue to be considered a reasonable option for patients who are currently on a highdose statin but have not reached their LDL-C goal, who cannot tolerate statins, or can only tolerate a low-dose statin. 6 One clinical-outcomes study, Improve-It, is under way. Led by physicians at Duke and Harvard universities, Improve-It is designed to test whether Vytorin (ezetimibe/simvastatin) reduces heart attacks, strokes, and death. 5 Surrogate marker studies, such as the use of imaging in the case of ENHANCE, cannot take the place of a welldesigned outcomes study. Patients and practicing clinicians want to know that a treatment will reduce undesired clinical events and prolong lives, not just alter an image. Unfortunately, the results from Improve-It are not expected until 2011.
What about the scientific issues not considered in the media? Thus far, LDL-C remains the most specific lipoprotein associated with CHD. 7 It can be considered the gold standard of cardiovascular risk factors with a long-standing track record. Only LDL-C has solid, well-accepted, evidence-based medicine supporting the fact that its reduction promotes an associated decrease in the incidence of acute and chronic cardiovascular events. 8 Despite a major push for high-dose statins by many physicians, the majority of LDL-C reduction with statin monotherapy is seen with the initial dose. Thereafter, each doubling of the dose, on average, reduces the LDL only another 6%. 9 Furthermore, the higher the statin dose, the more the problems, especially myopathy, as in the case of the data initially submitted to the FDA for each statin. A review of various studies shows a possible incidence of statin-related myopathy of up to 9% 10 despite some statements from short-term studies that there is no increase in myopathy with a high-dose statin. 11, 12 Therefore, if LDL-C lowering is the gold standard, a medication such as ezetimibe that can lower the LDL-C 13 approximately another 24% while keeping the statin at a safer, lower, long-term dose, still with the majority of statin benefit and pleiotropic effects, warrants further consideration. High-dose statin therapy appears established in selected situations such as in immediate association with the acute coronary syndrome. 11 However, high-dose statin therapy cannot claim specific long-term benefit versus a lower statin dose plus other medication as long as LDL-C less than 70 mg/dL is achieved, the new standard for the high risk cardiovascular patient. 12 Ezetimibe should not be cast aside because of a short-term, small, imaging, nonoutcomes study with the highest risk group of patients (heterozygous familial hypercholesterolemia) in which showing a significant difference between treatments may be the most difficult. In an upper 5% cardiovascular risk group of a population of US men, the Lipid Research Clinics required an average of 7.4 years of essentially only LDL-C lowering from cholestyramine versus placebo and no known pleiotropic effects to show significant benefit in reducing cardiovascular events. 14, 15 The same lengthy time period may be required to see benefit from LDL-C lowering by ezetimibe. Therefore, one practical approach to the everyday clinical use of ezetimibe may be to continue it in established patients doing well and with good LDL-C results but only start it in new patients who are unresponsive to other management until upcoming clinical-outcomes studies hopefully sort out the questions raised by ENHANCE and define whether ezetimibe has a significant role in CHD risk reduction.
